Kyverna Therapeutics and ElevateBio Sign Commercial Manufacturing and Supply Agreement for miv-cel: Key Milestone for Potential First-in-Class CAR T-Cell Therapy in Autoimmune Diseases
Key Highlights
- Kyverna Therapeutics (Nasdaq: KYTX) and ElevateBio announce a new commercial manufacturing and supply agreement for miv-cel, an autologous CD19-directed CAR T-cell therapy.
- The agreement ensures flexible and scalable supply of miv-cel to support anticipated U.S. commercial launches and global clinical trials, including for stiff person syndrome (SPS) and generalized myasthenia gravis (gMG).
- Kyverna continues to prepare for commercial launch with a rolling Biologics License Application (BLA) for miv-cel in SPS, on track for completion in the fourth quarter of 2026.
- If approved, miv-cel could become the first FDA-approved CAR T-cell therapy for an autoimmune disease and the first approved treatment for SPS.
- ElevateBio has demonstrated a clinical manufacturing success rate of over 98% for miv-cel in partnership with Kyverna.
Detailed Article
Kyverna Therapeutics, a late-stage clinical biopharmaceutical company specializing in cell therapies for autoimmune diseases, has entered into a pivotal commercial manufacturing and supply agreement with ElevateBio, a leading contract development and manufacturing organization (CDMO) focused on advanced therapies. This agreement, announced July 27, 2026, solidifies the commercial readiness of Kyverna’s lead candidate, miv-cel (mivocabtagene autoleucel, KYV-101), as it nears potential regulatory approval and market launch.
Implications for Shareholders and Market Impact
- Scalable Manufacturing Secured: The new agreement addresses one of the most critical aspects of commercial cell therapy—manufacturing scalability and reliability. This is particularly important as the company positions itself for launches in multiple indications and scales up to meet anticipated demand.
- Regulatory Progress: Kyverna remains on track to complete its rolling BLA submission for miv-cel in SPS with the FDA in Q4 2026. Approval would mark a first-in-class status for CAR T-cell therapy in autoimmune diseases, a potentially transformative and market-moving milestone.
- Track Record of Manufacturing Success: ElevateBio’s clinical manufacturing success rate of over 98% for miv-cel significantly de-risks the transition from clinical to commercial manufacturing, reducing one of the key risks in cell therapy commercialization.
- Potential First Approved Therapy for SPS: SPS is a rare and severe autoimmune condition with significant unmet medical need. If miv-cel is approved, it could capture first-mover advantage and address an underserved market, enhancing Kyverna’s commercial prospects.
- Expanded Franchise and Pipeline: Beyond SPS, Kyverna is advancing miv-cel in other autoimmune diseases such as generalized myasthenia gravis (gMG), multiple sclerosis, and rheumatoid arthritis. The company’s pipeline also includes next-generation CAR T-cell therapies, broadening future growth opportunities.
Leadership Commentary
“Kyverna’s highest priority is to bring the transformative potential of miv-cel to patients, and this agreement with ElevateBio further strengthens our commercialization readiness and long-term manufacturing supply as we prepare for launch in stiff person syndrome and future indications,” said Mayo Pujols, Chief Technology Officer of Kyverna.
Chris Murphy, CEO of ElevateBio, added, “By combining our technology and manufacturing expertise with Kyverna’s leadership in autoimmune cell therapies, we are well-positioned to deliver reliable supply that supports patients today and growing demand in the years ahead.”
About miv-cel (mivocabtagene autoleucel, KYV-101)
Miv-cel is a fully human, autologous, CD19-targeting CAR T-cell therapy with CD28 co-stimulation, designed for potency and tolerability. It is under investigation for B-cell-driven autoimmune diseases and is intended to deliver deep B-cell depletion and immune system reset, potentially achieving durable, drug-free remissions.
Company Overview
Kyverna Therapeutics is focused on developing curative cell therapies for autoimmune diseases. Its lead asset, miv-cel, has completed a registrational trial in SPS and is undergoing a registrational trial in gMG. The company is leveraging additional studies in multiple sclerosis and rheumatoid arthritis to inform future indications. Next-generation pipeline assets are also in development to improve patient access and experience.
ElevateBio provides advanced therapy manufacturing services and technologies, supporting partners across the product lifecycle with proprietary gene editing, cGMP manufacturing, and AI-powered process optimization.
Forward-Looking Statements and Risks
Investors should note that while Kyverna’s progress is significant, the company cautions that forward-looking statements are subject to risks, including regulatory uncertainties, market conditions, and the possibility that prior clinical results may not predict future outcomes. The ultimate commercial success of miv-cel will depend on FDA approval, market uptake, and the company’s ability to scale manufacturing and supply effectively.
Investor Relations Contacts
- Kyverna Investors: [email protected]
- Kyverna Media: [email protected]
- ElevateBio Investor Contact: Catherine Hu, [email protected]
- ElevateBio Media Contact: DJ Webster, [email protected]
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should consult the company’s filings and their financial advisor before making any investment decisions. The company’s prospects are subject to various risks as outlined in its SEC filings.
